288 INDUCING PLURIPOTENCY IN BOVINE SOMATIC STEM CELLS

2011 ◽  
Vol 23 (1) ◽  
pp. 242
Author(s):  
M. K. Addison ◽  
G. T. Gentry ◽  
R. A. Godke ◽  
K. R. Bondioli

Embryonic stem cells are pluripotent cells that can self-replicate indefinitely. There is an interest in producing pluripotent cells by reprogramming somatic cells. Porcine, murine, and human somatic cells are able to reprogram after exposure to viral vectors expressing Sox2, Oct-4, Klf4, and c-Myc. Exposure of somatic cells to these epigenetic modifying factors has been shown to increase expression of endogenous pluripotency factors, especially Oct-4 and Nanog. There have been limited attempts to induce pluripotency in bovine somatic cells. Bovine adipose-derived stem (ADS) cells were infected with a lentiviral vector expressing murine Sox2, Oct-4, Klf4, and c-Myc. In addition, bovine ADS cells were exposed to valproic acid (VPA), a histone deacetylase inhibitor, and zebularine (Zeb), a DNA methyltransferase 1 inhibitor. When two cell lines (‘A’ and ‘B’) of bovine ADS cells (between passages 2–6) were infected with the lentiviral vector, cells were able to form embryonic-stem-cell-like colonies on BD Matrigel (BD, Franklin Lakes, NJ, USA). Bovine ADS cells were exposed to lentiviral particles for 24 h and then changed to a Matrigel-coated culture dish after 3 days. These infected cells were stained on days 10 and 15 with an alkaline phosphatase stain, which resulted in positive staining cell colonies. The RNA was isolated from these cells, and expression of endogenous Oct-4 and Nanog was analysed by semiquantitative RT-PCR. The intensity of electrophoresis bands was compared between treatments as ratios of the gene of interest to an internal control gene, Poly A. The infected cells from each cell line had higher Oct-4 and Nanog expression than did noninfected cells from the same lines. For cell lines A and B, the ratios of Oct-4 increased from 0.87 to 1.27 and 2.38 to 8.77, respectively, for each line. The ratios for Nanog were also increased for A and B from 0.78 to 1.17 and 1.71 to 14.26, respectively. Furthermore, bovine ADS cells exposed to VPA and Zeb were also analysed for expression of endogenous Oct-4 and Nanog by semiquantitative RT-PCR. Bovine ADS cells from lines A and B described above were plated and allowed to culture overnight. After 24 h, the treatment group was changed to a culture medium containing 100 μM Zeb. Valproic acid (5 mM) was added to the treatment group 24 h later. The medium was changed for treatment and controls every 3 days (with the treatment group receiving Zeb and VPA). On day 14, RNA was isolated from cells of the control and treatment groups, and expression of endogenous Oct-4 and Nanog was analysed as described above. In cell line B, the expression of Oct-4 and Nanog was four times that of the control (with ratios of Oct-4 increasing from 0.20 to 0.82). However, in cell line A, the levels were slightly lower than those of the control (Oct-4 ratios decreased from 0.80 to 0.56). We hypothesise that increasing levels of Oct-4 and Nanog with epigenetic modifiers such as VPA or Zeb in conjunction with lentiviral expression vectors will result in higher induced pluripotency rates. This work was financed in part by a grant from the LSU System for the ACRES/LSU Collaborative Research Program.

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Javier Prieto ◽  
Josema Torres

Somatic cells can be reprogrammed into a pluripotent cellular state similar to that of embryonic stem cells. Given the significant physiological differences between the somatic and pluripotent cells, cell reprogramming is associated with a profound reorganization of the somatic phenotype at all levels. The remodeling of mitochondrial morphology is one of these dramatic changes that somatic cells have to undertake during cell reprogramming. Somatic cells transform their tubular and interconnected mitochondrial network to the fragmented and isolated organelles found in pluripotent stem cells early during cell reprogramming. Accordingly, mitochondrial fission, the process whereby the mitochondria divide, plays an important role in the cell reprogramming process. Here, we present an overview of the importance of mitochondrial fission in both cell reprogramming and cellular transformation.


2012 ◽  
Vol 111 (suppl_1) ◽  
Author(s):  
Zeeshan Pasha ◽  
Muhammad Ashraf

Aims: Owing to the ethical concerns for use of embryonic stem cells (ESC), adult somatic cells are attractive stem cell sources for reprogramming to pluripotency. We report here non-viral approach for reprogramming of skeletal myoblasts (SM) using a small molecule. Methods and Results: SM purified from young male Oct3/4-GFP+ transgenic mouse were treated for 5 days with valproic acid (VPA), a histone deacetylase (HDAC) inhibitor. Three weeks later, GFP+ colonies of SM derived iPSC (Sk-iPS) resembling with mouse embryonic stem cells were observed and propagated in vitro. SiPS were positive for alkaline phosphatase, had normal karyotype, expressed SSEA1, and induced teratomas in nude mice containing tissue comprising all three germ layers. RT PCR analysis showed that Sk-iPS cells expressed Oct4, Sox2, KLF4, c-Myc, Nanog and ESC specific pluripotency genes. HDAC1 activity was significantly reduced in Sk-iPs generated with valproic acid treatment as compared to ES cells. Sk-iPS derived embryoid bodies (EBs) yielded spontaneously contracting cardiomyocytes with morphological, molecular, and ultrastructural features of developing cardiomyocytes. These cells were also positive for early and late cardiac markers such as myosin heavy chain, Gata4, Mef-2c and Nkx2.5, Connexin-43 (P<0.01vs native SM). Micro RNA (miR) profiling showed abolition of let-7 family in Sk-iPS whereas ESC specific family of miR-290-295 was upregulated which indicated that Sk-iPS possessed miR profile similar to ESC. However muscle specific miRNAs (miR -133, -206) were identified in Sk-iPS cells as compared to ES cells indicating that the Sk-iPS retained the epigenetic memory of myogenic origin. Conclusions: We conclude that SM with endogenous expression of Sox2, KLF4, and cMyc are suitable candidates to generate iPS cells without viral vectors using a single small molecule.


Author(s):  
Y. Hong ◽  
R.B. Cervantes ◽  
E. Tichy ◽  
J.A. Tischfield ◽  
P.J. Stambrook

2006 ◽  
Vol 74 (4) ◽  
pp. 160-166 ◽  
Author(s):  
Shiro Iuchi ◽  
Meytha Marsch-Moreno ◽  
Cristina Velez-DelValle ◽  
Karen Easley ◽  
Walid Kuri-Harcuch ◽  
...  

2006 ◽  
Vol 18 (8) ◽  
pp. 839 ◽  
Author(s):  
Steven L. Stice ◽  
Nolan L. Boyd ◽  
Sujoy K. Dhara ◽  
Brian A. Gerwe ◽  
David W. Machacek ◽  
...  

Human and non-human primate embryonic stem (ES) cells are invaluable resources for developmental studies, pharmaceutical research and a better understanding of human disease and replacement therapies. In 1998, subsequent to the establishment of the first monkey ES cell line in 1995, the first human ES cell line was developed. Later, three of the National Institute of Health (NIH) lines (BG01, BG02 and BG03) were derived from embryos that would have been discarded because of their poor quality. A major challenge to research in this area is maintaining the unique characteristics and a normal karyotype in the NIH-registered human ES cell lines. A normal karyotype can be maintained under certain culture conditions. In addition, a major goal in stem cell research is to direct ES cells towards a limited cell fate, with research progressing towards the derivation of a variety of cell types. We and others have built on findings in vertebrate (frog, chicken and mouse) neural development and from mouse ES cell research to derive neural stem cells from human ES cells. We have directed these derived human neural stem cells to differentiate into motoneurons using a combination of developmental cues (growth factors) that are spatially and temporally defined. These and other human ES cell derivatives will be used to screen new compounds and develop innovative cell therapies for degenerative diseases.


2012 ◽  
Vol 86 (6) ◽  
Author(s):  
Masanori Takehashi ◽  
Masako Tada ◽  
Mito Kanatsu-Shinohara ◽  
Hiroko Morimoto ◽  
Yasuhiro Kazuki ◽  
...  

Blood ◽  
1997 ◽  
Vol 90 (7) ◽  
pp. 2591-2600 ◽  
Author(s):  
Roberta Morosetti ◽  
Dorothy J. Park ◽  
Alexey M. Chumakov ◽  
Isabelle Grillier ◽  
Masaaki Shiohara ◽  
...  

Human C/EBPε is a newly cloned CCAAT/enhancer-binding transcription factor. Initial studies indicated it may be an important regulator of human myelopoiesis. To elucidate the range of expression of C/EBPε, we used reverse transcription-polymerase chain reaction (RT-PCR) analysis and examined its expression in 28 hematopoietic and 14 nonhematopoietic cell lines, 16 fresh myeloid leukemia samples, and normal human hematopoietic stem cells and their mature progeny. Prominent expression of C/EBPε mRNA occurred in the late myeloblastic and promyelocytic cell lines (NB4, HL60, GFD8), the myelomonoblastic cell lines (U937 and THP-1), the early myeloblast cell lines (ML1, KCL22, MDS92), and the T-cell lymphoblastic leukemia cell lines CEM and HSB-2. For the acute promyelocytic leukemia cell line NB4, C/EBPε was the only C/EBP family member that was easily detected by RT-PCR. No C/EBPε mRNA was found in erythroid, megakaryocyte, basophil, B lymphoid, or nonhematopoietic cell lines. Most acute myeloid leukemia samples (11 of 12) from patients expressed C/EBPε. Northern blot and RT-PCR analyses showed that C/EBPε mRNA decreased when the HL60 and KG-1 myeloblast cell lines were induced to differentiate toward macrophages. Similarly, Western blot analysis showed that expression of C/EBPε protein was either unchanged or decreased slightly as the promyelocytic cell line NB4 differentiated down the macrophage-like pathway after treatment with a potent vitamin D3 analog (KH1060). In contrast, C/EBPε protein levels increased dramatically as NB4 cells were induced to differentiate down the granulocytic pathway after exposure to 9-cis retinoic acid. Furthermore, very early, normal hematopoietic stem cells (CD34+/CD38−), purified from humans had very weak expression of C/EBPε mRNA, but levels increased as these cells differentiated towards granulocytes. Likewise, purified granulocytes appeared to express higher levels of C/EBPε mRNA than purified macrophages. Addition of phosphothiolated antisense, but not sense oligonucleotides to C/EBPε, decreased clonal growth of HL-60 and NB4 cells by about 50% compared with control cultures. Taken together, our results indicate that expression of C/EBPε is restricted to hematopoietic tissues, especially myeloid cells as they differentiate towards granulocytes and inhibition of its expression in HL-60 and NB4 myeloblasts and promyelocytes decreased their proliferative capacity. Therefore, this transcriptional factor may play an important role in the process of normal myeloid development.


2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Leila Afshar ◽  
Hamid-Reza Aghayan ◽  
Jila Sadighi ◽  
Babak Arjmand ◽  
Seyed-Mahmoud Hashemi ◽  
...  

Abstract Background Regenerative medicine plays a major role in biomedicine, and given the ever-expanding boundaries of this knowledge, numerous ethical considerations have been raised. Main text Rapid advancement of regenerative medicine science and technology in Iran, emerged the Iranian National Committee for Ethics in Biomedical Research to develop a comprehensive national ethical guideline. Therefore, the present ethical guideline which comprises eleven chapters was developed in 2019 and approved in early 2020. The titles of these chapters were selected based on the ethical considerations of various aspects of the field of regenerative medicine: (1) ethical principles of research on stem cells and regenerative medicine; (2) ethical considerations for research on stem cells (embryonic stem cells, epiblast stem cells, tissue-specific stem cells, stem cells derived from transdifferentiation, induced pluripotent stem cells [iPSCs], germline pluripotent stem cells, germline stem cells, and somatic cell nuclear transfer [SCNT] stem cells); (3) ethical considerations for research on somatic cells in regenerative medicine (adult somatic cells, fetal tissue somatic cells, and somatic cells derived from pregnancy products [other than fetus]); (4) ethical considerations for research on gametes in regenerative medicine; (5) ethical considerations for research related to genetic manipulation (human and animal) in regenerative medicine; (6) ethical considerations for research on tissue engineering in regenerative medicine; (7) ethical considerations for pre-clinical studies in regenerative medicine; (8) ethical considerations for clinical trials in regenerative medicine; (9) ethical considerations for stem cells and regenerative medicine bio-banks; (10) ethical considerations for privacy and confidentiality; and (11) ethical considerations for obtaining informed consent. Conclusion This article discusses the process of developing the present ethical guidelines and its practical points. We hope that it can play an important worldwide role in advancing ethics of research on stem cells and regenerative medicine.


Sign in / Sign up

Export Citation Format

Share Document